NFKB1 and cancer: The final session on New Therapeutic Targets for Cirrhosis, HCC, and PDAC included the presentations on neutrophils, the NF-kB p50 subunit and exercise as interventional targets in liver inflammation and cancer by Derek Mann of Newcastle University; Metavert, a new therapeutic for treatment and prevention of metastasis in PDAC by Stephen Pandol of Cedars-Sinai Medical Center; precision medicine for HCC and pancreatic cancer by Shuji Tanaka of Tokyo Medical and Dental University; and epigenetics in liver fibrosis by Jelena Mann of Newcastle University.